UNSPSC 51151650: Methantheline

This classification denotes an antimuscarinic agent with the molecular formula C21H26NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 36EI79TX7I, chemically known as xanthene-9-carboxylic acid, ester with diethyl(2-hydroxyethyl)methylammonium bromide but generally known as methantheline, which bears US NIH Compound Identifier 4097. World Health Organization schedules methantheline in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, METHANTHELINE remains the US FDA Preferred Term for this commodity.

Methantheline bears US NLM identifiers UMLS ID C0025624 and NCI Concept Code C83951. SMILES: CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13..

UNSPSC 51151650 Methantheline is a Commodity code that captures pharmaceutical products procured by state and local health agencies, though recent solicitations under this code show minimal direct pharmaceutical purchasing and instead reflect broader health-system procurement activity. State and local governments buying under this code seek pharmaceutical supplies and health-related products to support community health initiatives, emergency response programs, and pharmacy benefit management. The issuing bodies include county health departments and state health and human services commissions, which use competitive bidding processes (IFB, RFI) to source these supplies. These jurisdictions typically require vendors to meet standard compliance certifications including drug-free workplace verification, E-Verify authorization, appropriate insurance coverage, and adherence to federal regulations when funding involves FEMA or similar sources.

Recent activity shows two distinct procurement approaches. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the county's community health building, with a response deadline of July 26, 2023, and a two-year initial contract term plus one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities regarding direct-to-manufacturer prescription programs that would bypass traditional pharmacy benefit managers and group purchasing organizations, seeking information on vendors' experience with self-insured employers and value-based contracting models. The code shows limited recent activity across state and local jurisdictions, with represented opportunities concentrated in Florida and Texas, suggesting modest procurement demand or potential code-classification misalignment with actual pharmaceutical purchasing patterns in state and local markets.